Aim: To investigate the actions of the muscarinic agonist carbachol on glutamate-induced neurotoxicity in PC12 cells, and the underlying mechanisms. Methods: PC12 cells were treated with different concentrations of glutamate for 24 or 48 h. The cell viability was measured using MTT assay, and the expression and activation of GSK-3β were detected with Western blot. β-Catenin translocation was detected using immunofluorescence. Luciferase reporter assay and real-time PCR were used to analyze the transcriptional activity of β-catenin. Results: Glutamate (1, 3, and 10 mmol/L) induced PC12 cell death in a dose-dependent manner. Moreover, treatment of the cells with glutamate (1 mmol/L) caused significant overactivation of GSK-3β and prevented β-catenin translocation to the nucleus. Pretreatment with carbachol (0.01 μmol/L) blocked glutamate-induced cell death and GSK-3β overactivation, and markedly enhanced β-catenin transcriptional activity. Conclusion: Activation of muscarinic receptors exerts neuroprotection in PC12 cells by attenuating glutamate-induced GSK-3β overactivation, suggesting potential benefits of muscarinic agonists for Alzheimer's disease.
Introduction
Alzheimer's disease (AD), a neurodegenerative disorder affecting patients worldwide, is associated with a loss of cholinergic neurons, which causes profound memory disturbances [1] . AD patients benefit from treatment with agonists of the muscarinic receptor (mAChR), which seem to restore lost cholinergic function [2, 3] . They also benefit from treatment with neuroprotective agents, which can alter the disease progression [4] . One novel therapeutic strategy for AD involves not only increasing cholinergic function but also slowing or stopping the pathological progression of the disease. Recent studies elucidating the mechanism by which muscarinic agonists protect cells from apoptosis induced by a variety of stimuli have suggested that the neuroprotective effects of mAChR activation may do more than address the symptoms of cognitive decline [5] [6] [7] [8] [9] . Rather, these agonists might affect the disease progression itself. The present study addressed the ability of these agonists to protect PC12 cells from glutamate-induced cell death and the mechanism underlying this process, as the Ca 2+ overload, oxidative stress and neuronal death associated with glutamate-induced excitotoxicity are thought to be key factors in the pathogenesis of AD [10] [11] [12] [13] [14] [15] . Glycogen synthase kinase-3β (GSK-3β), a serine/threonine kinase abundant in the central nervous system, plays an established role in cell survival [16, 17] . Several apoptotic stimuli appear to be involved in GSK-3β activation [18] . Aberrant overactivation of GSK-3β induces neuronal death [19] [20] [21] [22] [23] . Muscarinic agonists reduce tau hyperphosphorylation and counteract Aβ-toxicity, the hallmarks of AD, by inhibiting GSK-3β [7, 24] . This effect suggests that overactivation of GSK-3β could be attenuated through muscarinic signaling. The present work investigates whether overexpression or overactivation of GSK-3β plays a role in glutamate-mediated excitotoxicity and whether the GSK-3β/β-catenin signaling pathway plays a role in the protective effect of mAChR activation against glutamate-induced neurotoxicity.
Inhibition of GSK-3β activity and activation of mAChR are both therapeutic methods against AD [25] [26] [27] . This study may 
Immunoblots
In the current work, immunoblots were performed for various purposes and were adjusted for different protein samples. Cells were washed with PBS and lysed with a lysis buffer (50 mmol/L Tris-HCl, pH 7.5, 150 mmol/L NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mmol/L EDTA, 1 mmol/L sodium orthovanadate, 10 mmol/L sodium fluoride, 4 μg/mL leupeptin, 1 μg/mL aprotinin, and 100 μg/mL PMSF). Proteins were loaded onto 10% or 12% SDS-PAGE gels, transferred to nitrocellulose membranes, detected using the proper primary and secondary antibodies, and visualized using chemiluminescence (Pierce Biotechnology, USA). Various primary antibodies were used, including anti-phosphorSer9-GSK3β (1:500, KeyGEN, China), anti-total-GSK3β (1:500, KeyGEN, China), anti-β-catenin (1:1000, Abcam, UK), and anti-β-actin (1:5000, Abcam, UK).
Immunofluorescence
After treatment, PC12 cells were washed with PBS, fixed with 4% paraformaldehyde, and permeabilized with 0.2% Triton X-100. Endogenous cellular β-catenin was detected with polyclonal anti-β-catenin (1:1000) and fluorescent isothiocyanate (FITC)-conjugated anti-rabbit antibody (1:100, DAKO A/S, Denmark). Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). Cells were examined under an Axioplan 2 fluorescent microscope (Zeiss, Germany).
Luciferase reporter assays PC12 cells were cultured on a 10-cm dish and treated with a DNA mixture consisting of 8 μg of the appropriate TOPluciferase and 800 ng of the effector/control plasmids per well using Lipofectamine 2000 (Invitrogen, CA, USA). Cells were incubated with DNA/lipofectamine complexes for 5 h, then maintained in media with 10% FBS for 16 h and seeded in 24-well plates for post-treatment with 1 mmol/L glutamate. The luciferase (LUC) activity was assayed with the dualfirefly/Renilla luciferase reporter system (Promega, WI, USA) according to the manufacturer's instructions. Relative light units were measured in a Femtomaster FB12 chemiluminometer (Berthold, Pforzheim, Germany).
RT-PCR
Total RNA was extracted from 0.8×10 6 cells using TRIzol reagent (Gibco, CA, USA) according to the manufacturer's instructions. RNA concentration was measured by spectrophotometric measurement at 260 nm. cDNA was synthesized using random 9-mer primers and AMV reverse transcriptase (Takara, Shiga, Japan).
Plasmid constructs
The cDNA constructs for rat β-catenin were generated by PCR using the following primers containing Sal I and BamH I restriction sites: β-catenin-Sal I-forward: 5'-GCGTCGA-CACAATGGCTACTCAAG-3'; β-catenin-BamH I-reverse: 5'-CGCGGATCCTTACAGGTCGGTATC-3'. The PCR-amplified fragments were cut with Sal I/BamH I and cloned into the pEGFP-C1 plasmid (Clontech, CA, USA).
Real-time PCR
Up to 1 µL template cDNA was used. Thermal cycling conditions were 95 °C for 60 s, followed by 45 cycles of 95 °C for 30 s, 56 °C for 30 s and 72 °C for 35 s. Primer efficiency was >90%, which was confirmed with a standard curve spanning four orders of magnitude. After the reactions, the data were exported using 7300 System Software v1.3.0 (Applied Biosystems, CA, USA) and analyzed. The following primers were used (Table 1) .
Statistical analysis
The data are presented as the mean±SD. Statistical signifi- Table 1 . Primers for real-time PCR.
Gene Sequences Figure 1A ). We next assayed for GSK-3β phosphorylation in PC12 cells by immunoblotting with antibodies against phosphorylated GSK-3β (Ser9). After treating PC12 cells with 1, 3, or 10 mmol/L glutamate for 8 h, GSK-3β was overactivated, as indicated by decreased phosphorylation levels ( Figure 1B ). These results are consistent with previous reports demonstrating that GSK-3β could be negatively regulated by phosphorylation at Ser9 [28, 29] . However, phosphorylation levels at Ser9 did not change after 24 or 48 h glutamate treatment (data not shown).
GSK-3β participates in the Wnt pathway, which regulates β-catenin stability. The present work evaluated the intracellular distribution of β-catenin in PC12 cells during glutamate treatment. β-catenin nuclear localization was detected in transiently transfected PC12 cells using GFP-β-catenin. Cells incubated with 1 mmol/L glutamate displayed less β-catenin nuclear localization ( Figure 1C ). mAChR activation protected PC12 cells from glutamate-induced cell death and GSK-3β overactivation PC12 cells were pretreated with 0.001 μmol/L or 0.01 μmol/L muscarinic agonist carbachol for 24 h, followed by 3 mmol/L glutamate treatment for 48 h. The 0.001 μmol/L or 0.01 μmol/L carbachol pretreatment increased cell viability by 85.71%±4.9% and 94.55%±3.7%, respectively ( Figure 2A ). As 0.01 μmol/L carbachol elicited a more effective response, this concentration was used in subsequent cell signal transduction experiments. Carbachol treatment (0.01 μmol/L) diminished glutamate-evoked Ser9 GSK-3β phosphorylation deregulation ( Figure 2B ).
mAChR activation reversed glutamate repression of β-catenin nuclear translocation in PC12 cells
There was no change in β-catenin protein levels as detected by immunoblotting ( Figure 3A ). Immunofluorescence analysis with antibodies specific to β-catenin and the nuclear marker DAPI revealed less nuclear β-catenin in cells treated with 1 mmol/L glutamate than in untreated cells. Pretreatment Figure 3B ). Cytoplasm was extracted using a nuclear and cytoplasmic protein extraction kit and probed for β-catenin protein levels. Consistent with the decreased nuclear localization detected by immunofluorescence, higher levels of β-catenin were found in the cytoplasm after 1 mmol/L glutamate treatment by immunoblot. Carbachol attenuated this effect ( Figure 3C ).
Carbachol alleviated glutamate inhibition of β-catenin transcriptional activity in PC12 cells After accumulating and stabilizing in the cytoplasm, β-catenin translocates to the nucleus where it interacts with Tcf/LEF transcription factors, inducing the expression of Wnt target genes. These are important events in neural development and maintenance [30] . Glutamate inhibited β-catenin translocation to the nucleus. β-Catenin transcriptional activity was evaluated with a luciferase assay and by measuring mRNA levels of Wnt target genes after 1 mmol/L glutamate treatment for 8 h. PC12 cells were transfected using TOP-FLASH, which drives high levels of luciferase activity in response to Wnt signaling activity. Glutamate (1 mmol/L) treatment for 8 h decreased β-catenin transcriptional activity to 69.02% of control levels ( Figure 4A ). Exposure to glutamate reduced engrailed-2, connexin43, and cyclin D1 mRNA levels to 40.17%, 28.81%, and 43.60% of control levels, respectively. Pretreatment with 0.01 μmol/L carbachol increased transcriptional activity to 165.10% of control levels and increased engrailed-2, connexin43, and cyclin D1 mRNA levels to 304.56%, 93.36% and 156.23% control levels, respectively ( Figure 4B ).
Discussion
The hypothesis of glutamate excitotoxicity argues that excessive glutamate causes neuronal dysfunction and degeneration [14] . Understanding the mechanism underlying the excitotoxic process may lead to a better understanding of neurodegenerative disorders. The GSK-3β/β-catenin pathway has recently been shown to modulate many fundamental cell processes, and GSK-3β itself is involved in the pathology of AD [31, 32] . Among cell lines of neuronal origin, PC12 cells are selectively affected by the cytotoxic effect of glutamate [33] . The present work utilized a well-established experimental method where PC12 cells are treated with glutamate. Glutamateinduced neurotoxicity was accompanied by GSK-3β overactivation, which was inhibited by mAChR.
Previous studies demonstrated that glutamate can decrease GSK-3β activity in hippocampal slices, which may contribute to neurotoxicity in the hippocampus [34] . The present work established that glutamate causes PC12 cell death in a dosedependent manner, accompanied by GSK-3β overactivation. Unlike most kinases, GSK-3β is constitutively active in cells. Activity can be dynamically inhibited by phosphorylation at Ser9 and stimulated by phosphorylation at Tyr216 [35] . Unlike previous publications, which measured phosphorylation at Tyr216, the present work evaluated phosphorylation at Ser9. Ser9 phosphorylation renders GSK-3β inactive and thus is implicated in neuronal survival [21] . Glutamate decreased GSK-3β phosphorylation at Ser9, indicating that GSK-3β is overactivated during glutamate-induced neurotoxicity. Consistent with these findings, glutamate led to GSK-3β activation, resulting in reduced accumulation of nuclear β-catenin and reduced enhancement of transcriptional activity.
Next, we demonstrated that the muscarinic agonist carbachol protects PC12 cells from glutamate-induced cytotoxicity. mAChR is primarily responsible for these neuroprotective effects, as these effects can be antagonized by an mAChR or M1 mAChR antagonist. This finding is consistent with the view that activation of G q/11 -coupled mAChR can protect cells against apoptosis induced by variety of stimuli [8] . This finding is also consistent with recent reports stating that mAChR activation has neuroprotective effects in attenuating the progression of AD [5] . More importantly, the present work established that the neuroprotective effect of carbachol occurs through the inhibition of GSK-3β during glutamate treatment. These find- www.chinaphar.com Ma K et al Acta Pharmacologica Sinica npg ings are highly interesting in light of the well-established link between cell survival and GSK-3β: while apoptotic processes involve GSK-3β activation, anti-apoptotic signaling includes GSK-3β inhibition [21, 36, 37] . Inactivation of GSK-3β by phosphorylation at Ser9 can increase the stabilization of β-catenin, which promotes its nuclear translocation [38] . Augmented β-catenin signaling is an anti-apoptotic stimulus [39] . To further examine the finding that mAChR activation can inhibit glutamate-induced GSK-3β overactivation, we assayed the stability and localization of β-catenin. After treatment with 1 mmol/L glutamate, the total quantity of β-catenin did not change, but less β-catenin localized to the nuclei, which decreased its transcriptional activity. Carbachol reversed these effects of glutamate.
In summary, AD is a complex disorder of the central nervous system. Different etiological hypotheses on the origins of AD are based on different histopathological lesions found in the brains of AD patients. mAChR has long been a highprofile target for AD treatment because its manipulation may restore cholinergic hypofunction. Small-molecule inhibitors of GSK-3β have also attracted significant attention because GSK-3β is a key signaling molecule in the etiology of AD [40, 41] . Our study provides evidence that GSK-3β may be directly involved in pathways leading to glutamate-induced cell death and that mAChR activation exerts a neuroprotective effect by inhibiting GSK-3β overactivation. These results provide a new explanation for the benefits experienced by AD patients treated with mAChR activation -mAChR activation inhibits the overactivation of the GSK-3β signaling pathway.
